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Objectives The aim of this study was to evaluate the relative efficacy and safety of zotarolimus-eluting stents (ZES) in com-
parison with the established and widely used sirolimus- (SES) and paclitaxel-eluting stents (PES) in routine clinical
practice.
Background Whether ZES might provide similar clinical and angiographic outcomes in a broad spectrum of patients com-
pared with SES or PES is undetermined.
Methods We performed a single-blind, multicenter, prospectively randomized trial to compare ZES with SES and PES in
2,645 patients undergoing percutaneous coronary intervention. The primary end point was a composite of major
adverse cardiac events (MACE) (death, myocardial infarction, and ischemia-driven target vessel revasculariza-
tion) at 12 months. A noninferiority comparison (ZES vs. SES) and a superiority comparison (ZES vs. PES) were
performed for the primary end point.
Results Baseline clinical and angiographic characteristics were similar in the 3 groups. At 12 months, the ZES group
showed noninferior rates of MACE compared with the SES group (10.2% vs. 8.3%, p for noninferiority  0.01,
p for superiority  0.17) and significantly fewer MACE than the PES group (10.2% vs. 14.1%, p for superiority 
0.01). The incidence of death or myocardial infarction was similar among the groups (ZES vs. SES vs. PES, 5.8%
vs. 6.9% vs. 7.6%, respectively, p  0.31). The incidence of stent thrombosis was significantly lower in the SES
group (ZES vs. SES vs. PES, 0.7% vs. 0% vs. 0.8%, respectively, p  0.02).
Conclusions In this large-scale, practical randomized trial, the use of ZES resulted in similar rates of MACE compared with SES and
in fewer MACE compared with PES at 12 months. (Comparison of the Efficacy and the Safety of Zotarolimus-Eluting
Stent Versus Sirolimus-Eluting Stent and PacliTaxel-Eluting Stent for Coronary Lesions; NCT00418067) (J Am Coll
Cardiol 2010;56:1187–95) © 2010 by the American College of Cardiology Foundation
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ZES Versus SES and PES October 5, 2010:1187–95The 2 polymer-based drug-eluting
stents (DES) approved by the U.S.
Food and Drug Administration—
sirolimus-eluting stents (SES) and
paclitaxel-eluting stents (PES)—
have reduced angiographic reste-
nosis and the need for repeat
revascularization compared with
bare-metal stents (BMS) (1–3).
On the basis of the results of
pivotal clinical trials, these DES
have been widely used for percu-
taneous coronary intervention
(PCI) in daily practice, including
more complex clinical and ana-
tomic subsets (4). However, the
long-term safety of the 2 DES has
been questioned by recent studies,
which have reported increased
ates of late stent thrombosis and late-occurring death or
yocardial infarction (MI) compared with BMS (5,6).
The zotarolimus-eluting stent (ZES) is a newer DES
sing zotarolimus, a synthetic analog of sirolimus with a
imilar mechanism of action and a biocompatible phospho-
ylcholine polymer, coated onto a low-profile, thin-strut,
obalt-alloy stent (7). Despite the marked benefit of ZES
ompared with BMS (8), there are currently limited data
omparing ZES with the established and widely used SES
nd PES in routine clinical practice. We therefore con-
ucted a randomized, controlled trial to compare the relative
fficacy and safety of ZES with SES and PES in patients
ndergoing PCI.
ethods
tudy design and population. The ZEST (Comparison of
he Efficacy and Safety of Zotarolimus-Eluting Stent with
niversity Dongsan Medical Center, Daegu, Korea; ¶¶Ulsan University Hospital,
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ersity Sacred Heart Hospital, Anyang, Korea; ‡‡‡Daegu Catholic University
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 Pusan National University Hospital, Pusan, Korea; and the ¶¶¶Kyung Pook
ational University Hospital, Daegu, Korea. This study was supported by funds from
he CardioVascular Research Foundation, Seoul, Korea, and Medtronic Vascular, Santa
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Abbreviations
and Acronyms
BMS  bare-metal stent(s)
DES  drug-eluting stent(s)
MI  myocardial infarction
PCI  percutaneous
coronary intervention
PES  paclitaxel-eluting
stent(s)
SES  sirolimus-eluting
stent(s)
TLR  target lesion
revascularization
TVR  target vessel
revascularization
ZES  zotarolimus-eluting
stent(s)m
Manuscript received October 8, 2009; revised manuscript received January 13,
010, accepted March 2, 2010.irolimus-Eluting and PacliTaxel-Eluting Stent for Coro-
ary Lesions) trial was a prospective, randomized, single-
lind, controlled study conducted in 19 centers in Korea
etween October 2006 and January 2008. The study pro-
ocol was approved by the ethics committee at each partic-
pating center and was conducted according to the principles
f the Declaration of Helsinki. All patients provided writ-
en, informed consent for participation in this trial. The
ponsor of this study contributed to study design but had no
ole in data collection, monitoring, analysis, interpretation,
r in the writing of the manuscript.
We sought to enroll consecutive patients age 18 years or
lder with either stable angina or acute coronary syndromes
ho had at least 1 coronary lesion (defined as stenosis of
ore than 50%) suitable for stent implantation. There were
o limitations on the number of lesions or vessels or on the
ength of the lesions, reflecting routine clinical practice.
xclusion criteria were ST-segment elevation MI necessi-
ating primary PCI; severely compromised ventricular dys-
unction (ejection fraction 25%) or cardiogenic shock;
llergy to antiplatelet drugs, heparin, stainless steel, contrast
gents, zotarolimus, sirolimus, or paclitaxel; left main cor-
nary artery disease (defined as stenosis of more than 50%);
n-stent restenosis of drug-eluting stents; terminal illness;
nd participation in another coronary-device study.
andomization, procedures, and adjunct drug therapy.
andomization was performed after diagnostic angiography
nd before PCI. Eligible patients were randomly assigned
n a 1:1:1 basis to treatment with ZES (Endeavor,
edtronic Vascular, Santa Rosa, California), SES (Cypher
elect, Cordis, Johnson & Johnson, Miami Lakes, Florida),
r PES (Taxus Liberte, Boston Scientific, Natick, Massa-
husetts) by means of an interactive web response system.
he allocation sequence was computer-generated, stratified
ccording to participating center and the presence or ab-
ence of diabetes mellitus and diffuse long lesions (lesion
ength more than 28 mm by visual estimate), and blocked
ith block sizes of 6 and 9 varying randomly.
The PCI was performed according to standard tech-
iques. The same randomly assigned stent had to be
mplanted in all lesions in patients requiring multi-lesion
nterventions, except when the assigned stent could not be
nserted, in which case crossover to another device was
llowed.
Before or during the procedure, all patients received at
east 100 mg of aspirin and a 300- to 600-mg loading dose
f clopidogrel. Heparin was administered throughout the
rocedure to maintain an activated clotting time of 250 s or
onger. Administration of glycoprotein IIb/IIIa inhibitors
as at the discretion of the operator. After the procedure, all
atients received 100 mg/day of aspirin indefinitely as well
s 75 mg/day clopidogrel for at least 12 months.
atient follow-up and data management. Adverse events
ere assessed in the hospital and at 30 days and 4, 9, and 12
onths. All eligible patients were asked to return for an
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October 5, 2010:1187–95 ZES Versus SES and PESngiographic follow-up between 8 and 10 months after the
rocedure or earlier if anginal symptoms occurred.
All outcomes of interest were confirmed by source doc-
mentation collected at each hospital and were centrally
djudicated by an independent clinical events committee,
hose members were blinded as to the assigned stent. An
ndependent data and safety monitoring board reviewed the
ata periodically to identify potential safety issues, but there
ere no formal stopping rules.
uantitative coronary angiography. Coronary angio-
rams were digitally recorded at baseline, immediately after
he procedure, and at follow-up and were assessed offline in
he angiographic core laboratory (Asan Medical Center,
eoul, Korea) with an automated edge-detection system
CAAS V, Pie Medical Imaging, Maastricht, the Nether-
ands) by experienced assessors unaware of the allocated
tent. Standard qualitative and quantitative analyses and
efinitions were used for angiographic analysis (9). The
eference diameter was determined by interpolation.
All quantitative angiographic measurements were ob-
ained within the stented segment (in-stent) and over the
ntire segment including the stent and its 5-mm proximal
nd distal margins (in-segment). Measured variables included
he diameter of the reference vessel, the minimal luminal
iameter, the degree of stenosis (%), and late luminal loss (the
ifference between the minimal luminal diameter after the
ost-procedure and at follow-up). Binary restenosis was de-
ned as percentage diameter stenosis of 50% or greater on
ollow-up angiography, and restenosis patterns were qualita-
ively assessed with the Mehran classification (10).
tudy end points and definitions. The primary end point
as a composite of major adverse cardiac events (i.e., death
rom any cause, MI, and ischemia-driven target vessel revas-
ularization [TVR]) within 12 months. Secondary clinical end
oints included the individual components of the primary
utcome, composite of death or MI, ischemia-driven target
esion revascularization (TLR), and stent thrombosis. Second-
ry angiographic end points were in-stent and in-segment late
oss and binary restenosis at 9 months angiography.
All deaths were considered to have been from cardiac
auses unless a noncardiac cause could be identified. The
iagnosis of MI was based on the presence of new Q waves
n at least 2 contiguous leads or an elevation of creatine
inase or its MB isoenzyme to at least 3 times the upper
imit of the normal range. Revascularization was defined as
schemia-driven if there was stenosis of at least 50% of the
iameter, as documented by a positive functional study,
schemic changes on an electrocardiogram, or ischemic
ymptoms or, in the absence of documented ischemia, if
here was stenosis of at least 70% as assessed by quantitative
oronary analysis. The occurrence of stent thrombosis was
ssessed by the Academic Research Consortium definition
11). Device success was defined as a final stenosis of 30%
f the vessel diameter after implantation of the assigned
tent only, and treatment success was defined as a final ftenosis of 30% of the vessel diameter with the use of any
ercutaneous intervention.
tatistical analysis. On the basis of previous clinical trials
SIRIUS [Sirolimus-Eluting Balloon-Expandable Stent in
he Treatment of Patients with De Novo Native Coronary-
rtery Lesions] [2], TAXUS-IV [3], TAXUS-V [12],
IRTAX [Sirolimus-Eluting Versus Paclitaxel-Eluting
tents for Coronary Revascularization] [13], ISAR-
IABETES [Intracoronary Stenting and Angiographic
esults: Do Diabetic Patients Derive Similar Benefit From
aclitaxel-Eluting and Sirolimus-Eluting Stents] [14],
ONG-DES II [Randomized Comparison of the Efficacy
f Sirolimus-Eluting Stent Versus Paclitaxel-Eluting Stent
n the Treatment of Long Native Coronary Lesions trial]
15], and the ENDEAVOR-I [16] and ENDEAVOR-II [8]
tudies; the ENDEAVOR-III [17] and ENDEAVOR-VI
7] results were not yet available at the time of our study
esign), we assumed an incidence of primary end point of
% in the SES group, 11% in the ZES, and 17% in the PES
roup. Based on our alternative hypothesis that ZES might
e noninferior to SES and superior to PES, the primary
nalysis was therefore a noninferiority comparison (with a
oninferiority margin of 5%) between ZES and SES and a
uperiority comparison between ZES and PES. The non-
nferiority margin was based on historical data, clinically
cceptable relevance, and the feasibility of study recruit-
ent. We intended to give 90% power to the study and
hose an alpha level of 0.025 (corrected by the Bonferroni
ethod for the 2 planned comparisons in the primary
nalysis). For the noninferiority testing with a noninferiority
argin of 5% and a 1-sided 2.5% significance level, 475
atients were needed to have 90% power to reject the null
ypothesis if it was false. For the superiority testing,
nrollment of 861 patients would provide the study with a
tatistical power of 90% to detect the difference with a
-sided significant level of 0.025. To fulfill the assumptions for
he 2 primary comparisons with a 2.0% allowance for attrition,
sample size of 2,640 patients (880 patients in each group) was
alculated with PASS software (NCSS, Kaysville, Utah).
oninferiority would be declared if the 1-sided 97.5% upper
onfidence limit for the difference was not 5%.
All analyses were based on the intention-to-treat princi-
le. Differences among treatment groups were evaluated by
nalysis of variance for continuous variables and by the
hi-square or Fisher exact test for categorical variables.
umulative event curves were generated by means of the
aplan-Meier method. The noninferiority and superiority
ypothesis was assessed statistically with Z test, by which
-sided p values for noninferiority were calculated to com-
are differences between groups with margins of noninferi-
rity, and the log-rank test, respectively.
We pre-specified stratified analyses of the primary out-
ome according to the presence or absence of 3 characteristics:
iabetes, diffuse long lesion (if at least 1 of the treated lesions
as 28 mm), and bifurcation lesion. We additionally per-
ormed post-hoc analyses stratified according to acute coronary
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ZES Versus SES and PES October 5, 2010:1187–95yndromes, lesion in the left anterior descending artery, mul-
ivessel disease, and small vessel disease (if at least 1 of the
reated lesions had a reference vessel diameter 2.75 mm).
For angiographic subgroup analyses, we used general linear
ixed models and generalized estimation equation logistic
odels with robust standard errors that allowed for correlation
f more than 1 lesion within patients to compare characteristics
f lesions between groups at baseline and follow-up.
Analyses were performed with the use of SAS software
ersion 9.1 (SAS Institute, Cary, North Carolina). No
djustments were made for multiple comparisons in second-
ry analyses. All p values and confidence intervals are
-sided, apart from those from noninferiority testing of the
rimary end point for comparison between ZES and SES.
esults
aseline characteristics and procedural results. Between
ctober 2006 and January 2008, a total of 2,645 patients
3,613 lesions) were enrolled in the study and randomly
ssigned to receive ZES (883 patients; 1,190 lesions), SES
Baseline Clinical Characteristics of the PatientsTable 1 Baseline Clinical Characteristics of
ZES (n  883
Age, yrs 61.7 9.3
Male sex 586 (66.4)
Body mass index, kg/m2 24.9 2.9
Diabetes mellitus
Any diabetes 268 (30.4)
Requiring insulin 32 (3.6)
Hypertension 552 (62.5)
Hyperlipidemia 466 (52.8)
Current smoker 236 (26.7)
Family history of CAD 48 (5.4)
Previous coronary angioplasty 75 (8.5)
Previous bypass surgery 6 (0.7)
Previous myocardial infarction 30 (3.4)
Previous congestive heart failure 9 (1.0)
Cerebrovascular disease 65 (7.4)
Peripheral vascular disease 15 (1.7)
Multivessel disease 414 (46.9)
Left ventricular ejection fraction, % 61 8
Clinical indication
Silent ischemia 48 (5.4)
Chronic stable angina 348 (39.4)
Unstable angina 410 (46.4)
NSTEMI 77 (8.7)
Discharge medications
Aspirin 882 (99.9)
Clopidogrel 876 (99.2)
Warfarin 3 (0.3)
Statin 698 (79.0)
ACE inhibitor 343 (38.8)
Angiotensin II-receptor antagonist 235 (26.6)
Beta-blocker 581 (65.8)
Calcium-channel blocker 460 (52.1)
Values given are mean  SD or n (%). Data are given for the intention
ACE  angiotensin-converting enzyme; CAD  coronary artery disea
PES  paclitaxel-eluting stent(s); SES  sirolimus-eluting stent(s); ZES  zot878 patients; 1,218 lesions), or PES (884 patients; 1,205
esions). Baseline clinical, angiographic, and procedural char-
cteristics were similar among the groups (Tables 1 and 2).
he rates of device success and treatment success were similar
or the 3 study groups.
linical outcomes. Adverse events during follow-up are
hown in Table 3. At 1 month, the incidence of clinical
vents was similar among the groups, except that there
as a trend toward a lower incidence of early thrombosis
n the SES group compared with the other devices.
Clinical follow-up at 12 months was completed for 2,603 of
he 2,645 patients (98.4%): 870 of 883 (98.5%) in the ZES
roup, 864 of 878 (98.4%) in the SES group, and 869 of 884
98.3%) in the PES group (p  0.93). At 12 months, the
ncidence of the primary end point was 10.2% in patients
eceiving ZES, 8.3% in patients receiving SES, and 14.1% in
atients receiving PES, demonstrating that ZES was not
nferior to SES (p for noninferiority  0.01, p for superiority 
.17) and was superior to PES (p for superiority  0.01)
Fig. 1, Table 3). The incidence of death or MI was similar
atients
SES (n  878) PES (n  884) p Value
61.9 9.6 62.0 9.6 0.80
591 (67.3) 582 (65.8) 0.80
25.0 3.1 25.0 2.9 0.88
247 (28.1) 245 (27.7) 0.42
33 (3.8) 36 (4.1) 0.88
517 (58.9) 540 (61.1) 0.29
451 (51.4) 446 (50.5) 0.62
256 (29.2) 243 (27.5) 0.51
44 (5.0) 52 (5.9) 0.72
82 (9.3) 83 (9.4) 0.76
6 (0.7) 5 (0.6) 0.94
39 (4.4) 41 (4.6) 0.37
4 (0.5) 7 (0.8) 0.41
55 (6.3) 53 (6.0) 0.47
21 (2.4) 17 (1.9) 0.57
430 (49.0) 410 (46.4) 0.51
61 8 61 8 0.59
0.73
44 (5.0) 56 (6.3)
343 (39.1) 343 (38.8)
424 (48.3) 403 (45.6)
67 (7.6) 82 (9.3)
873 (99.4) 880 (99.5) 0.24
874 (99.5) 881 (99.7) 0.42
7 (0.8) 6 (0.7) 0.45
720 (82.0) 715 (80.9) 0.29
312 (35.5) 315 (35.6) 0.26
222 (25.3) 242 (27.4) 0.60
562 (64.0) 594 (67.2) 0.37
481 (54.8) 439 (49.7) 0.10
t population.the P
)
-to-trea
se; NSTEMI  non–ST-segment elevation myocardial infarction;
arolimus-eluting stent(s).
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October 5, 2010:1187–95 ZES Versus SES and PESmong the groups. There were significant differences among
he 3 groups in the rates of TLR and TVR (Table 3).
At 12 months, the cumulative frequency of definite or
robable stent thrombosis was 0.7% with ZES and 0.8% with
ES, and there was no case with SES. There were 3 cases of
ate stent thrombosis: 1 patient (121 days after stenting,
topping aspirin and clopidogrel 55 days after the procedure
ecause of patient’s noncompliance) in the ZES group, and 2
atients (54 days after stenting on dual antiplatelet therapy and
90 days after stenting, 5 days after stopping aspirin and
lopidogrel because of a tooth extraction) in the PES group.
ll of the cases were related to de novo thrombosis and not to
epeated procedures. The rates of antithrombotic treatment
ere similar among the groups during follow-up.
The findings for the primary end point were consistent
cross the pre-specified stratified analyses for diabetes,
iffuse long lesions, and bifurcation lesions as well as in
ther important post hoc subgroups (acute coronary
yndrome, lesions in the left anterior descending artery,
Baseline Lesions and Procedural CharacteristicsTable 2 Baseline Lesions and Procedural Ch
ZE
(n  1,190
Lesion characteristics
Location
Left anterior descending 622
Left circumflex 252
Right coronary 316
Coronary graft 0
ACC-AHA B2 or C type 858
Total occlusion 68
Thrombus-containing 32
Bifurcation lesions 181
Ostial lesion 85
Restenotic lesion 5
Calcification
None or mild 1,129
Moderate 40
Severe 21
Lesion length, mm
10 73
10–20 466
20 651
Procedural characteristics
No. of stents/lesion 1.2
No. of stents/patient 1.6
Length of stents/lesion, mm 27.9
Length of stents/patient, mm 39.7
Maximal stent diameter, mm 3.4
Maximal pressure, atm 16.3
Direct stenting 86
Intravascular ultrasound guidance 488
Use of glycoprotein IIb/IIIa inhibitors/patient 19
Device success 1,164
Treatment success 1,186
Values given are n (%) or mean  SD. Data are given for the intention
ACC  American College of Cardiology; AHA  American Heart Assultivessel disease, and small vessel disease) (Fig. 2). tngiographic results. Quantitative angiographic results at
aseline, after procedure, and at follow-up are shown in Table
. Angiographic measurements of lesions before and after
he procedure were similar in the groups. Angiographic
ollow-up at 9 months was completed in 1,849 of 2,645
atients (69.9%): 623 (70.6%) in the ZES group, 599
68.2%) in the SES group, and 627 (70.9%) in the PES
roup (p  0.41). Patients undergoing angiographic
ollow-up were younger (p  0.001); less likely to have
iabetes (p  0.001), hypertension (p  0.03), previous
I (p  0.006), or multivessel disease (p  0.004); and
ore likely to have higher ejection fraction (p  0.001)
han those who did not return for angiographic follow-up.
Among patients undergoing angiographic follow-up, base-
ine clinical, angiographic, and procedural characteristics were
imilar among the groups. The mean (SD) in-stent late
uminal loss was 0.53 0.53mm in the ZES, 0.15 0.35mm
n the SES, and 0.46  0.52 mm in the PES groups (p 
.001). The rate of in-segment binary restenosis was 12.1% in
teristics
ns)
SES
(n  1,218 Lesions)
PES
(n  1,205 Lesions) p Value
0.39
645 (53.0) 611 (50.7)
225 (18.5) 253 (21.0)
348 (28.6) 340 (28.2)
0 1 (0.1)
921 (75.6) 895 (74.3) 0.14
76 (6.2) 96 (8.0) 0.07
37 (3.0) 38 (3.2) 0.78
151 (12.4) 166 (13.8) 0.14
72 (5.9) 82 (6.8) 0.45
12 (1.0) 13 (1.1) 0.16
0.77
1,145 (94.0) 1,132 (93.9)
43 (3.5) 46 (3.8)
30 (2.5) 27 (2.2)
0.09
71 (5.8) 61 (5.1)
444 (36.5) 504 (41.8)
703 (57.7) 640 (53.1)
1.2 0.4 1.2 0.4 0.35
1.6 0.9 1.6 0.9 0.92
28.9 13.5 28.9 14.3 0.12
38.3 24.3 38.9 25.2 0.48
3.4 0.7 3.5 0.6 0.03
16.3 4.1 16.2 4.2 0.95
110 (9.0) 89 (7.4) 0.19
514 (42.2) 491 (40.7) 0.74
15 (1.7) 14 (1.6) 0.64
1,198 (98.4) 1,176 (97.6) 0.40
1,215 (99.8) 1,200 (99.6) 0.77
t population.
; other abbreviations as in Table 1.arac
S
Lesio
(52.3)
(21.2)
(26.6)
(72.1)
(5.7)
(2.7)
(15.2)
(7.1)
(0.4)
(94.9)
(3.4)
(1.8)
(6.1)
(39.2)
(54.7)
0.5
0.9
13.1
26.8
0.7
4.2
(7.2)
(41.0)
(2.2)
(97.8)
(99.7)he ZES, 2.4% in the SES, and 12.4% in the PES group
(
T
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ZES Versus SES and PES October 5, 2010:1187–95p  0.001). By per-lesion basis analysis, the incidences of
LR were consistent with those for per-patients analysis
ZES vs. SES vs. PES, 4.2% vs.0.6% vs. 5.5%, respectively,
 0.001). The incidences of primary end point in the
ngiographic subgroups were 10.4% for ZES, 8.2% for SES,
nd 15.3% for PES (p  0.001). There was no interaction
etween treatment effect and the presence or absence of
linical Events at Follow-UpTable 3 Clinical Events at Follow-Up
Clinical Outcomes ZES (n  883)
Follow-up at 1 month
Death 3 (0.3)
Cardiac 3 (0.3)
Noncardiac 0
Myocardial infarction 44 (5.0)
Q-wave 3 (0.3)
Non–Q-wave 41 (4.6)
Death or myocardial infarction 45 (5.1)
Ischemia-driven target lesion revascularization 3 (0.3)
Percutaneous 3 (0.3)
Surgical 0
Ischemia-driven target vessel revascularization 3 (0.3)
Percutaneous 3 (0.3)
Surgical 0
Stent thrombosis
Definite 3 (0.3)
Definite or probable 5 (0.6)
Any 5 (0.6)
Major adverse cardiac events 45 (5.1)
Follow-up at 12 months
Death 6 (0.7)
Cardiac 5 (0.6)
Noncardiac 1 (0.1)
Myocardial infarction 47 (5.3)
Q-wave 5 (0.6)
Non–Q-wave 42 (4.8)
Death or myocardial infarction 51 (5.8)
Ischemia-driven target lesion revascularization* 43 (4.9)
Percutaneous 43 (4.9)
Surgical 0
Ischemia-driven target vessel revascularization* 46 (5.2)
Percutaneous 46 (5.2)
Surgical 0
Stent thrombosis
Definite* 4 (0.5)
Definite or probable* 6 (0.7)
Acute 1 (01)
Subacute 4 (0.5)
Late 1 (0.1)
Any* 7 (0.8)
Primary end point† 90 (10.2)
ercentages are from the intention-to-treat analysis. The p values were calculated with the chi-squa
linical end points. No adjustments were made for multiple comparisons in secondary analyses: f
.001); for target vessel revascularization (ZES vs. SES: p  0.001, ZES vs. PES: p  0.04, and SE
ES vs. PES: p  0.03); for definite or probable stent thrombosis (ZES vs. SES: p  0.03, ZES vs. P
ES: p 0.62, and SES vs. PES: p 0.02). †For primary end point (defined as composite of death
est and p  0.17 from superiority test for comparison of ZES with SES, and p  0.01 from supe
Abbreviations as in Table 1.ngiographic follow-up (p for interaction  0.50). Addi- Tionally, angiographic follow-up did not significantly affect
he primary outcome (p  0.25).
iscussion
n this large-scale, randomized, multicenter trial, ZES was
oninferior to SES and was superior to PES in the
omposite end point of death, MI, and ischemia-driven
SES (n  878) PES (n  884) p Value
1 (0.1) 1 (0.1) 0.55
1 (0.1) 1 (0.1) 0.55
0 0 —
54 (6.2) 60 (6.8) 0.27
3 (0.3) 3 (0.3) 0.99
51 (5.8) 57 (6.4) 0.25
54 (6.2) 60 (6.8) 0.32
0 4 (0.5) 0.17
0 4 (0.5) 0.17
0 0 —
0 4 (0.5) 0.17
0 4 (0.5) 0.17
0 0 —
0 4 (0.5) 0.17
0 5 (0.6) 0.06
0 5 (0.6) 0.06
54 (6.2) 60 (6.8) 0.32
7 (0.8) 10 (1.1) 0.57
3 (0.3) 5 (0.6) 0.83
4 (0.5) 5 (0.6) 0.28
55 (6.3) 62 (7.0) 0.34
3 (0.3) 5 (0.6) 0.83
52 (5.9) 57 (6.4) 0.29
61 (6.9) 67 (7.6) 0.31
12 (1.4) 66 (7.5) 0.001
11 (1.3) 65 (7.4) 0.001
1 (0.1) 1 (0.1) 0.78
16 (1.8) 67 (7.6) 0.001
15 (1.7) 66 (7.5) 0.001
1 (0.1) 1 (0.1) 0.78
0 6 (0.7) 0.04
0 7 (0.8) 0.02
0 1 (0.1) 0.99
0 4 (0.5) 0.14
0 2 (0.2) 0.78
1 (0.1) 9 (1.0) 0.05
73 (8.3) 125 (14.1) 0.001
or Fisher exact test, as appropriate. *The p values of post hoc multiple comparisons for secondary
t lesion revascularization (ZES vs. SES: p  0.001, ZES vs. PES: p  0.02, and SES vs. PES: p 
ES: p  0.001); for definite stent thrombosis (ZES vs. SES: p  0.12, ZES vs. PES: p  0.75, and
0.99, and SES vs. PES: p  0.02); and for any stent thrombosis (ZES vs. SES: p  0.07, ZES vs.
rdial infarction, and ischemia-driven target-vessel revascularization), p 0.01 from noninferiority
st for comparison of ZES with PES.re test
or targe
S vs. P
ES: p 
, myoca
riority teVR at 12 months. Rate of death or MI at 1 year was
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October 5, 2010:1187–95 ZES Versus SES and PESimilar among the 3 groups, whereas the rate of stent
hrombosis in the ZES group was similar with the PES
roup but higher than the SES group.
Several clinical studies have compared SES and PES.
irolimus was found be more effective as a site-specific agent
han paclitaxel in reducing neointimal growth and repeat
evascularization (13,14,18). On the basis of these out-
Figure 1 Kaplan-Meier Cumulative Event Curves
for the Primary End Point
The p value for comparison of zotarolimus-eluting stent (ZES) with sirolimus-
eluting stent (SES) is 1-sided from noninferiority test with a Z test, and p value
for comparison of ZES with paclitaxel-eluting stent (PES) is 2-sided from superi-
ority test with a log-rank test. I bars indicate 95% confidence intervals.
Figure 2 Subgroup Analysis of Primary End Point in Comparing
Probability for interaction represents the likelihood for interaction between the vari
CI  confidence interval; other abbreviations as in Figure 1.omes, our primary hypothesis was that late-coming ZES
ight be noninferior to SES and superior to PES. Although
everal new DES are being developed and used in current
ractice, there have been limited data comparing these
ewer stents with the established SES and PES in various
ypes of patients, including those with more complicated
esions and in acute settings. Therefore our study is a
ell-powered, randomized trial that compared the relative
fficacy and safety of ZES simultaneously with well-proven
ES and PES. Although subgroup findings should be
onsidered hypothesis-generating, major findings were con-
istent across high-risk subpopulations (i.e., diabetes, long
esions, small vessels, and multivessel disease). Accordingly,
ur findings can be extended to a broader spectrum of
atients and provide a high level of generalizability to
outine clinical practice.
Theoretically, an acceptable mild degree of neointimal
roliferation of ZES might provide a reasonable compro-
ise between safety and efficacy. By contrast, in this trial,
he incidence of stent thrombosis during 1 year was
igher in the ZES and the PES groups than in the SES
roup. These findings are similar to recent results from
he SORT OUT (The Danish Organization on Random-
zed Trials With Clinical Outcome) III (19) and
NDEAVOR-IV trial (7). However, larger studies with
onger-term follow-up are needed to provide information
or relative long-term safety beyond 1 year, which is
ndeed the main concern with DES use.
Routine angiographic follow-up is known to increase
he rate of repeat revascularization by the ocul-stenotic
With SES and PES
nd the relative treatment effect.ZES
able a
r
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ZES Versus SES and PES October 5, 2010:1187–95eflex (20). However, in the current study, we did not find
significant interaction between treatment effect and
ystematic repeat angiography, suggesting that the rela-
ive performance of the study devices was consistent
cross the angiography follow-up cohort and nonangiog-
aphy follow-up cohorts. In addition, repeat angiography
id not affect the primary outcome by risk factor
nalysis.
Although the present study excluded only patients with
T-segment elevation MI and left main disease, both of
hich might be associated with larger vessel size, the vessel
ize of the study group was larger than that reported in
Quantitative Angiographic AnalysisTable 4 Quantitative Angiographic Analysis
ZES
(n  1,190 L
Before procedure
Lesion length, mm 23.7 1
Reference vessel diameter, mm 2.99 0
Minimal luminal diameter, mm 0.98 0
Diameter stenosis, % 67.2 1
Immediately after procedure
Minimal luminal diameter, mm
In stent 2.63 0
In segment 2.30 0
Diameter stenosis, %
In stent 9.8 9
In segment 17.8 1
Acute gain, mm
In stent 1.65 0
In segment 1.31 0
Follow-up at 9 months
No. of lesions with follow-up angiography 841
Minimal luminal diameter, mm*
In stent 2.12 0
In segment 2.00 0
Diameter stenosis, %*
In stent 28.3 1
In segment 30.6 1
Late luminal loss, mm*
In stent 0.53 0
In segment 0.30 0
Binary restenosis, %*
In stent 9.6
In segment 12.1
Restenosis pattern, %
Focal 6.2
Diffuse 3.9
Proliferative 1.1
Total occlusion 0.8
Values are mean  SD. *The p values of post hoc multiple compariso
for multiple comparisons of continuous variables in secondary angiogra
ZES vs. PES: p  0.20, and SES vs. PES: p  0.001); for in-segment m
SES vs. PES: p 0.001); for in-stent diameter stenosis (ZES vs. SES: p
diameter stenosis (ZES vs. SES: p  0.001, ZES vs. PES: p  0.99, and
vs. PES: p 0.01, and SES vs. PES: p 0.001); for in-segment late loss
for in-stent restenosis (ZES vs. SES: p  0.001, ZES vs. PES: p  0.83
p  0.001, ZES vs. PES: p  0.99, and SES vs. PES: p  0.001).
Abbreviations as in Table 1.revious comparative trials (13,21,22). Therefore, there is lhe possibility that a larger vessel size might attenuate
ifferences between stents.
In this trial, the use of intravascular ultrasound during the
rocedure was more common compared with those in
estern countries (23). Although the clinical impact of
ntravascular ultrasound in DES placement is not yet clear,
igher usage of intravascular ultrasound might partly con-
ribute to the relatively lower incidence of stent thrombosis
ompared with the rates reported in previous trials
13,19,24).
The most consistent finding of the ZEST trial is that
ES is associated with lowest angiographic restenosis, with
)
SES
(n  1,218 Lesions)
PES
(n  1,205 Lesions) p Value
24.3 12.2 24.4 12.5 0.38
3.01 0.50 3.00 0.50 0.72
0.99 0.51 0.97 0.50 0.62
66.9 15.7 67.7 15.6 0.52
2.61 0.46 2.61 0.46 0.34
2.32 0.51 2.30 0.52 0.69
10.7 9.0 11.1 8.8 0.004
17.4 9.5 18.2 9.8 0.23
1.61 0.55 1.63 0.56 0.40
1.32 0.57 1.32 0.59 0.91
840 840
2.48 0.49 2.17 0.62 0.001
2.23 0.50 2.00 0.59 0.001
15.7 12.3 26.5 17.7 0.001
21.5 12.1 30.3 17.3 0.001
0.15 0.35 0.46 0.52 0.001
0.11 0.35 0.32 0.51 0.001
1.8 10.9 0.001
2.4 12.4 0.001
2.1 7.7 0.001
0.3 4.1 0.001
0 0.4 0.01
0 0.1 0.02
econdary angiographic outcomes. Bonferroni corrections were made
alyses; for in-stent minimal luminal diameter (ZES vs. SES: p 0.001,
uminal diameter (ZES vs. SES: p  0.001, ZES vs. PES: p  0.99, and
1, ZES vs. PES: p 0.09, and SES vs. PES: p 0.001); for in-segment
s. PES: p  0.001); for in-stent late loss (ZES vs. SES: p  0.001, ZES
. SES: p 0.001, ZES vs. PES: p 0.41, and SES vs. PES: p 0.001);
ES vs. PES: p  0.001); and for in-segment restenosis (ZES vs. SES:esions
2.0
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October 5, 2010:1187–95 ZES Versus SES and PEShrombosis among the 3 tested types of DES. This might
uggest that newer DES platforms are not always better
han older ones. Given that current evidence for the first 2
pproved DES supports a sustained long-term clinical effect
n a broad population of patients, new DES must prove
linical efficacy and safety in both long-term follow-up as
ell as in complex subsets.
tudy limitations. Given the relatively infrequent occur-
ence of the safety outcomes (death, MI, and stent throm-
osis), substantially larger patient populations are required
o detect small differences in event rates. At the inception of
he study design, the noninferiority margin was based on
istorical data, clinically acceptable relevance, and the fea-
ibility of recruitment. Given that a relative ratio of effect
izes between 0.8 and 1.25 has been historically reasonable
o imply equivalence, we acknowledge that our noninferi-
rity margin is too wide, and this noninferiority might have
een nonsignificant with a larger cohort of patients. If the
pper limit of the 1-sided 95% confidence interval of 1.25
n a relative risk scale might be planned for such an analysis,
he necessary sample size would be more than 6,650 patients
n each arm. Another limitation of our study was the
elatively short follow-up period of 12 months. The ongo-
ng, post-approval, large randomized PROTECT (Patient
elated OuTcomes with Endeavor versus Cypher stenting
rial)—comparing ZES and SES in 8,800 patients with the
rimary end point of definite or probable thrombosis at 3
ears—will provide a critical appraisal of relative safety (25).
onclusions
ur practical randomized trial showed that ZES resulted in
imilar rates of major adverse cardiac events compared with
ES and in fewer events compared with PES at 1 year.
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